91111威斯尼斯人(中国)官方网站-BinG百科
About US
About US
Introduction
Our Value
History
Contact Us
Join Us
Patients
Patients
Patients
Peripheral Arterial Disease
Peripheral Arteriosclerosis
Peripheral Venous Disease
Varicosity
Peripheral Arterial Disease
Peripheral Venous Disease
Peripheral Arteriosclerosis
Varicosity
Professional Medical Solutions
Professional Medical Solutions
Products
Peripheral Artery
PTA Catheter
ATK DCB Dilatation catheter
BTK DCB Dilatation Catheter
Support Catheter
Peripheral Cone-shaped Balloon Dilation Catheter
Peripheral Vein
Peripheral Vascular Aspiration System
Endovenous RF Closure System
Second Generation Peripheral Vascular Aspiration S
Maintenance Of Arteriovenous Fistula Access
DCB Dilatation Catheter for Hemodialysis Access
Peripheral Scoring Balloon Dilatation Catheter
Neurovascular
Endocranial Balloon Dilatation Catheter
Coronary Artery
Coronary Artery Balloon Dilatation Catheter
RT-Zero Coronary Artery Balloon Dilatation Cathete
Vericor-14 Microtubule
Academic
Peripheral Artery
Peripheral Vein
Maintenance Of Arteriovenous Fistula Access
Neurovascular
Coronary Artery
PTA Catheter
ATK DCB Dilatation catheter
BTK DCB Dilatation Catheter
Support Catheter
Peripheral Cone-shaped Balloon Dilation Catheter
Peripheral Vascular Aspiration System
Endovenous RF Closure System
Second Generation Peripheral Vascular Aspiration S
DCB Dilatation Catheter for Hemodialysis Access
Peripheral Scoring Balloon Dilatation Catheter
Endocranial Balloon Dilatation Catheter
Coronary Artery Balloon Dilatation Catheter
RT-Zero Coronary Artery Balloon Dilatation Cathete
Vericor-14 Microtubule
News
News
Corporate News
R&D Progress
Investor Relations
News
All
Corporate News
R&D Progress
Latest Info
2024-03-26
Acotec reports 2023 annual results: full-year revenue of $474 million, up 20% year-over-year, as second growth curve matures
2022-12-17
Acotec Holdings, LLC and Boston Scientific Corporation Announce Partial Offer and Collaboration Between Them
Acotec reports 2023 annual results: full-year revenue of $474 million, up 20% year-over-year, as second growth curve matures
2024-03-26
Acotec and Boston Scientific Sign Master Collaboration Agreement and Master Service Agreement
2023-07-20
Acotec and Boston Scientific Sign Memorandum of Understanding
2023-06-19
91111威斯尼斯人官方AcoStream™二代获NMPA批准上市
2023-04-13
Acotec Reports 2022 Annual Results: full-year revenue of $396 million, up 30% year-over-year
2023-04-13
Acotec Holdings, LLC and Boston Scientific Corporation Announce Partial Offer and Collaboration Between Them
2022-12-17
91111威斯尼斯人官方NEO-Skater颅内球囊扩张导管获批上市
2022-12-14
91111威斯尼斯人官方外周一次性使用支撑导管(Vericor)获美国FDA批准注册
2022-11-12
91111威斯尼斯人官方2022中期业绩发布:营收1.75亿元,同比增长25%,增长点多元化
2022-08-27
91111威斯尼斯人官方外周一次性使用支撑导管(Vericor)获批上市
2022-07-14
91111威斯尼斯人官方AcoArt Orchid®&Dhalia™ DCB用于血液透析患者自体动静脉瘘狭窄(AVF)PTA术适应症的拓展获批
2022-07-13
91111威斯尼斯人官方射频消融全套设备获批上市 静脉领域布局再获突破
2022-04-18
91111威斯尼斯人官方发布2021年业绩报告:全年营收3.04亿元,同比增长56.6%,调整后净利润同比增长140.4%
2022-03-30
道阻且长 行则将至 | 91111威斯尼斯人官方2021年终盘点
2022-01-30
91111威斯尼斯人官方向美国FDA递交ACOART LITOS™紫杉醇涂层经皮腔内血管成形术(PTA)球囊导管的IDE申请
2022-01-29
91111威斯尼斯人官方披露2021年年度经营数据预测:年度营收和毛利较去年同比实现大幅增长
2022-01-24
中国药监局受理91111威斯尼斯人官方动静脉导入DCB产品上市许可申请
2022-01-19
91111威斯尼斯人官方荣膺格隆汇“年度最具创新力IPO”奖
2021-12-15
91111威斯尼斯人官方抽吸导管获批上市 外周介入先发优势快速扩张
2021-11-12
Load more information